ClinicalTrials.gg
CompletedNCT01194830Updated Jan 29, 2014Results posted

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

A Phase 3 interventional study of Linagliptin and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 93 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-01-29.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
29th of 67
234 · median 175
Started
2010
with 7 others
Phase 3
31 of 67
none open now
Registered
20th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 29th largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Dated written that is in accordance with GCP and local legislation.
  2. Male and female Black / African American patients
  3. Diagnosis of type 2 diabetes at least 3 months prior to the informed consent.
  4. more than or equal to 7.5% and less than or equal to 11% at Visit 1.
  5. Patients are currently treatment-naive or being treated with up to one oral antidiabetic medication. Antidiabetic medication is to be unchanged for at least 10 weeks prior to the informed consent.
  6. Age more than 18 and less than 80 years at Visit 1 (Screening).
  7. (Body Mass Index) less than 45 kg/m2 at Visit 1.

Exclusion criteria

Exclusion criteria:

  1. Myocardial infarction (MI), stroke or (TIA) within 3 months of .
  2. Type 1 diabetes.
  3. Impaired hepatic function, defined by serum levels of either (ALT, SGPT), aspartate aminotransferase (AST, SGOT), or alkaline phosphatase above 3 x (ULN) as determined at Visit 1.
  4. Known prior or allergy to the product or its .
  5. Treatment with insulin within 3 months prior to informed consent.
  6. Treatment with anti-obesity drugs (e.g., sibutramine, orlistat, rimonabant) within three months prior to informed consent or initiating therapy during the study.
  7. Any prior use of dipeptidyl peptidase-4 (DPP-4) inhibitors.
  8. Glucagon-like peptide-1 (GLP-1) agonists are excluded 3 months prior to informed consent.
  9. History of alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation as assessed by the Investigator.
  10. Participation in another trial with an investigational drug within 3 months prior to informed consent or during the study.
  11. Pre-menopausal women (last menstruation less than 1 year prior to informed consent) who:

    • are nursing or pregnant
    • are not surgically sterile
    • or are of and are not practicing an acceptable method of or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intrauterine devices/systems (IUDs / IUSs), oral, implantable or injectable contraceptives, and vasectomised partners. No exceptions will be made.

    Hormonal birth control should have been in use for at least three months prior to signing informed consent and continue at least until the next menstrual period after completing the study.

  12. Current treatment with chronic use of systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
  13. History of bariatric surgery.
  14. Patients who have demonstrated an inability to be compliant (80-120%) with the dosing regimen during the placebo run-in period.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
234 participants (actual)

Study arms

  • Active comparator
    Linagliptin

    1 Tablet PO QD

    Drug: Linagliptin

  • Placebo comparator
    Placebo

    1 Tablet PO QD

    Drug: Placebo

Interventions

  • Active drug 1 tablet PO QD

  • DrugPlacebo

    1 Tablet PO QD

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: baseline, 24 weeks

Secondary outcomes

  1. Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: baseline, 6 weeks

  2. Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: baseline, 12 weeks

  3. Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: baseline, 18 weeks

  4. Occurrence of Absolute Efficacy Response (HbA1c < 7%) After 24 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: 24 weeks

  5. Occurrence of Absolute Efficacy Response (HbA1c < 6.5%) After 24 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: 24 weeks

  6. Occurrence of Relative Efficacy Response (Reduction in HbA1c >= 0.5%) After 24 Weeks

    Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

    Time frame: 24 weeks

  7. Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks

    Time frame: baseline, 24 weeks

  8. Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks

    Time frame: baseline, 24 weeks

07

Results

Posted Oct 26, 2012
Limitations and caveats
Eight randomized subjects were excluded from all analysis due to overall data integrity issues at the site

Participant flow

Participant flow — Overall Study
MilestonePlacebo TabletLinagliptin 5 mg Tablet
Started124110
Completed8883
Not completed3627
Withdrew: Adverse event32
Withdrew: Protocol violation54
Withdrew: Lost to follow-up97
Withdrew: Withdrawal by subject21
Withdrew: Lack of efficacy11
Withdrew: Non-compliance issues44
Withdrew: Other reason128

Outcome measures

PrimaryChange From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
baseline, 24 weeks
Reported as:
Least squares mean · Percentage
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks
PercentagePlacebo TabletLinagliptin 5 mg Tablet
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks-0.25 ± 0.16-0.84 ± 0.15
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = 0.0005 · Least squares mean difference: -0.58 · 95% CI -0.91 to -0.26ANCOVA model included terms for treatment, baseline HbA1c and number of other Oral Antidiabetic Drugs
SecondaryChange From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
baseline, 6 weeks
Reported as:
Least squares mean · Percentage
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks
PercentagePlacebo TabletLinagliptin 5 mg Tablet
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 6 Weeks-0.22 ± 0.10-0.64 ± 0.09
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = <0.0001 · Least squares mean difference: -0.42 · 95% CI -0.62 to -0.22ANCOVA model included terms for treatment, baseline HbA1c and number of other Oral Antidiabetic Drugs
SecondaryChange From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
baseline, 12 weeks
Reported as:
Least squares mean · Percentage
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks
PercentagePlacebo TabletLinagliptin 5 mg Tablet
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 12 Weeks-0.17 ± 0.14-0.72 ± 0.13
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = 0.0002 · Least squares mean difference: -0.55 · 95% CI -0.84 to -0.26ANCOVA model included terms for treatment, baseline HbA1c and number of other Oral Antidiabetic Drugs
SecondaryChange From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
baseline, 18 weeks
Reported as:
Least squares mean · Percentage
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks
PercentagePlacebo TabletLinagliptin 5 mg Tablet
Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 18 Weeks-0.26 ± 0.14-0.81 ± 0.14
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = 0.0003 · Least squares mean difference: -0.55 · 95% CI -0.85 to -0.26ANCOVA model included terms for treatment, baseline HbA1c and number of other Oral Antidiabetic Drugs
SecondaryOccurrence of Absolute Efficacy Response (HbA1c < 7%) After 24 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
24 weeks
Reported as:
Number · Participants
Occurrence of Absolute Efficacy Response (HbA1c < 7%) After 24 Weeks
ParticipantsPlacebo TabletLinagliptin 5 mg Tablet
Responder (HbA1c < 7.0%)1026
Non-responder (HbA1c >= 7.0%)10072
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · Regression, Logistic · p = 0.0010 · Odds ratio (or): 4.063 · 95% CI 1.764 to 9.358
SecondaryOccurrence of Absolute Efficacy Response (HbA1c < 6.5%) After 24 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
24 weeks
Reported as:
Number · Participants
Occurrence of Absolute Efficacy Response (HbA1c < 6.5%) After 24 Weeks
ParticipantsPlacebo TabletLinagliptin 5 mg Tablet
Responder (HbA1c < 6.5%)29
Non-responder (HbA1c >= 6.5%)10889
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · Regression, Logistic · p = 0.0352 · Odds ratio (or): 5.433 · 95% CI 1.124 to 26.260
SecondaryOccurrence of Relative Efficacy Response (Reduction in HbA1c >= 0.5%) After 24 Weeks

Glycosylated hemoglobin is reported as a percentage of the total hemoglobin

Time frame:
24 weeks
Reported as:
Number · Participants
Occurrence of Relative Efficacy Response (Reduction in HbA1c >= 0.5%) After 24 Weeks
ParticipantsPlacebo TabletLinagliptin 5 mg Tablet
Responder (reduction in HbA1c >= 0.5%)3353
Non-responder (reduction in HbA1c < 0.5%)7745
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · Regression, Logistic · p = 0.0003 · Odds ratio (or): 2.951 · 95% CI 1.651 to 5.274
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks
Time frame:
baseline, 24 weeks
Reported as:
Least squares mean · mg/dL (milligrams per deciliter)
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks
mg/dL (milligrams per deciliter)Placebo TabletLinagliptin 5 mg Tablet
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks-11.0 ± 6.6-22.9 ± 6.4
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = 0.0972 · Least squares mean difference: -12.0 · 95% CI -26.1 to 2.2ANCOVA model included terms for treatment, baseline HbA1c, baseline FPG, and number of other Oral Antidiabetic Drugs
SecondaryChange From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks
Time frame:
baseline, 24 weeks
Reported as:
Least squares mean · mg/dL (milligrams per deciliter)
Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks
mg/dL (milligrams per deciliter)Placebo TabletLinagliptin 5 mg Tablet
Change From Baseline in 2-hour Post-prandial Glucose (PPG) After 24 Weeks-36.77 ± 23.76-38.74 ± 22.77
Statistical analysis
  • Placebo Tablet vs Linagliptin 5 mg Tablet · ANCOVA · p = 0.9368 · Least squares mean difference: -1.97 · 95% CI -53.80 to 49.86ANCOVA model included terms for treatment, baseline HbA1c, baseline 2-hour PPG, and number of other Oral Antidiabetic Drugs

Adverse events

Collected over 24 weeks (from day of first dose until 7 days after last dose). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Tablet—2/120 (1.7%)15/120 (12.5%)
Linagliptin 5 mg Tablet—1/106 (0.9%)9/106 (8.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo TabletLinagliptin 5 mg Tablet
Acute myocardial infarctionCardiac disorders0/1201/106
BronchitisInfections and infestations0/1201/106
Food allergyImmune system disorders1/1200/106
PneumoniaInfections and infestations1/1200/106
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/1200/106
AngioedemaSkin and subcutaneous tissue disorders1/1200/106
Most frequent other events
Most frequent other events
EventPlacebo TabletLinagliptin 5 mg Tablet
HyperglycaemiaMetabolism and nutrition disorders11/1203/106
Urinary tract infectionInfections and infestations4/1207/106

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo TabletLinagliptin 5 mg TabletTotal
Mean54.1 ± 9.953.7 ± 10.153.9 ± 9.9
Age, Customized
Age, Customized(Number of participants)Placebo TabletLinagliptin 5 mg TabletTotal
< 65 years10489193
65 to 74 years121426
>= 75 years437
Sex: Female, Male
Sex: Female, Male(Participants)Placebo TabletLinagliptin 5 mg TabletTotal
Female5946105
Male6160121
Weight
Weight(kilograms)Placebo TabletLinagliptin 5 mg TabletTotal
Mean99.02 ± 20.1695.83 ± 20.9697.52 ± 20.55
Weight categories
Weight categories(Number of participants)Placebo TabletLinagliptin 5 mg TabletTotal
<= 70 kilograms2810
> 70 to 80 kilograms211839
> 80 to 90 kilograms252651
> 90 kilograms7254126
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter)Placebo TabletLinagliptin 5 mg TabletTotal
Mean33.35 ± 5.3632.04 ± 6.1032.74 ± 5.74
Body Mass Index (BMI) categories
Body Mass Index (BMI) categories(Number of participants)Placebo TabletLinagliptin 5 mg TabletTotal
< 30 kilograms/square meter334578
>= 30 kilograms/square meter8761148
Height
Height(centimeters)Placebo TabletLinagliptin 5 mg TabletTotal
Mean172.1 ± 10.9172.8 ± 10.3172.4 ± 10.6

3 further baseline measures are reported on the registry.

08

Study locations

93 sites
  • 1218.75.059 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 1218.75.054 Boehringer Ingelheim Investigational Site
    Huntsville, Alabama, United States
  • 1218.75.035 Boehringer Ingelheim Investigational Site
    Mobile, Alabama, United States
  • 1218.75.101 Boehringer Ingelheim Investigational Site
    Toney, Alabama, United States
  • 1218.75.066 Boehringer Ingelheim Investigational Site
    Little Rock, Alaska, United States
  • 1218.75.008 Boehringer Ingelheim Investigational Site
    Pell City, Alaska, United States
  • 1218.75.071 Boehringer Ingelheim Investigational Site
    Anaheim, California, United States
  • 1218.75.018 Boehringer Ingelheim Investigational Site
    Chino, California, United States
  • 1218.75.081 Boehringer Ingelheim Investigational Site
    Garden Grove, California, United States
  • 1218.75.109 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 1218.75.040 Boehringer Ingelheim Investigational Site
    Colorado Springs, Colorado, United States
  • 1218.75.047 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 1218.75.106 Boehringer Ingelheim Investigational Site
    Bartow, Florida, United States
  • 1218.75.098 Boehringer Ingelheim Investigational Site
    Bradenton, Florida, United States
  • 1218.75.036 Boehringer Ingelheim Investigational Site
    Chiefland, Florida, United States
  • 1218.75.105 Boehringer Ingelheim Investigational Site
    Fort Lauderdale, Florida, United States
  • 1218.75.083 Boehringer Ingelheim Investigational Site
    Fort Myers, Florida, United States
  • 1218.75.002 Boehringer Ingelheim Investigational Site
    Hialeah, Florida, United States
  • 1218.75.080 Boehringer Ingelheim Investigational Site
    Jacksonville, Florida, United States
  • 1218.75.065 Boehringer Ingelheim Investigational Site
    Jupiter, Florida, United States
  • 1218.75.007 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1218.75.029 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1218.75.045 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1218.75.084 Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • 1218.75.017 Boehringer Ingelheim Investigational Site
    Ocala, Florida, United States
  • 1218.75.012 Boehringer Ingelheim Investigational Site
    Pinellas Park, Florida, United States
  • 1218.75.074 Boehringer Ingelheim Investigational Site
    Port Orange, Florida, United States
  • 1218.75.076 Boehringer Ingelheim Investigational Site
    South Miami, Florida, United States
  • 1218.75.003 Boehringer Ingelheim Investigational Site
    St. Petersburg, Florida, United States
  • 1218.75.039 Boehringer Ingelheim Investigational Site
    St. Petersburg, Florida, United States
  • 1218.75.075 Boehringer Ingelheim Investigational Site
    Tallahassee, Florida, United States
  • 1218.75.100 Boehringer Ingelheim Investigational Site
    Tamarac, Florida, United States
  • 1218.75.015 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 1218.75.103 Boehringer Ingelheim Investigational Site
    West Palm Beach, Florida, United States
  • 1218.75.049 Boehringer Ingelheim Investigational Site
    Atlanta, Georgia, United States
  • 1218.75.067 Boehringer Ingelheim Investigational Site
    Calhoun, Georgia, United States
  • 1218.75.016 Boehringer Ingelheim Investigational Site
    Dunwoody, Georgia, United States
  • 1218.75.063 Boehringer Ingelheim Investigational Site
    Lawrenceville, Georgia, United States
  • 1218.75.056 Boehringer Ingelheim Investigational Site
    Marietta, Georgia, United States
  • 1218.75.026 Boehringer Ingelheim Investigational Site
    Rosswell, Georgia, United States
  • 1218.75.079 Boehringer Ingelheim Investigational Site
    Sandy Springs, Georgia, United States
  • 1218.75.034 Boehringer Ingelheim Investigational Site
    Snellville, Georgia, United States
  • 1218.75.001 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 1218.75.055 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 1218.75.069 Boehringer Ingelheim Investigational Site
    Owensboro, Kentucky, United States
  • 1218.75.044 Boehringer Ingelheim Investigational Site
    Baton Rouge, Louisiana, United States
  • 1218.75.108 Boehringer Ingelheim Investigational Site
    Essex, Maryland, United States
  • 1218.75.086 Boehringer Ingelheim Investigational Site
    Brockton, Massachusetts, United States
  • 1218.75.087 Boehringer Ingelheim Investigational Site
    Watertown, Massachusetts, United States
  • 1218.75.051 Boehringer Ingelheim Investigational Site
    Detroit, Michigan, United States
  • 1218.75.088 Boehringer Ingelheim Investigational Site
    Flint, Michigan, United States
  • 1218.75.099 Boehringer Ingelheim Investigational Site
    Biloxi, Mississippi, United States
  • 1218.75.006 Boehringer Ingelheim Investigational Site
    Atco, New Jersey, United States
  • 1218.75.004 Boehringer Ingelheim Investigational Site
    Camden, New Jersey, United States
  • 1218.75.031 Boehringer Ingelheim Investigational Site
    Brooklyn, New York, United States
  • 1218.75.095 Boehringer Ingelheim Investigational Site
    Brooklyn, New York, United States
  • 1218.75.038 Boehringer Ingelheim Investigational Site
    Asheboro, North Carolina, United States
  • 1218.75.009 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 1218.75.023 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 1218.75.060 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 1218.75.005 Boehringer Ingelheim Investigational Site
    Greensboro, North Carolina, United States
  • 1218.75.107 Boehringer Ingelheim Investigational Site
    High Point, North Carolina, United States
  • 1218.75.020 Boehringer Ingelheim Investigational Site
    Jacksonville, North Carolina, United States
  • 1218.75.027 Boehringer Ingelheim Investigational Site
    Winston Salem, North Carolina, United States
  • 1218.75.096 Boehringer Ingelheim Investigational Site
    Akron, Ohio, United States
  • 1218.75.090 Boehringer Ingelheim Investigational Site
    Columbus, Ohio, United States
  • 1218.75.078 Boehringer Ingelheim Investigational Site
    Dayton, Ohio, United States
  • 1218.75.037 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1218.75.082 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1218.75.010 Boehringer Ingelheim Investigational Site
    Uniontown, Pennsylvania, United States
  • 1218.75.028 Boehringer Ingelheim Investigational Site
    Uniontown, Pennsylvania, United States
  • 1218.75.091 Boehringer Ingelheim Investigational Site
    Anderson, South Carolina, United States
  • 1218.75.072 Boehringer Ingelheim Investigational Site
    Columbia, South Carolina, United States
  • 1218.75.068 Boehringer Ingelheim Investigational Site
    Greenwood, South Carolina, United States
  • 1218.75.097 Boehringer Ingelheim Investigational Site
    Greer, South Carolina, United States
  • 1218.75.024 Boehringer Ingelheim Investigational Site
    Brentwood, Tennessee, United States
  • 1218.75.025 Boehringer Ingelheim Investigational Site
    Collierville, Tennessee, United States
  • 1218.75.011 Boehringer Ingelheim Investigational Site
    Germantown, Tennessee, United States
  • 1218.75.042 Boehringer Ingelheim Investigational Site
    Humboldt, Tennessee, United States
  • 1218.75.030 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 1218.75.050 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 1218.75.053 Boehringer Ingelheim Investigational Site
    Dallas, Texas, United States
  • 1218.75.057 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1218.75.064 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1218.75.104 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1218.75.043 Boehringer Ingelheim Investigational Site
    Houton, Texas, United States
  • 1218.75.022 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1218.75.058 Boehringer Ingelheim Investigational Site
    Sugar Land, Texas, United States
  • 1218.75.033 Boehringer Ingelheim Investigational Site
    Tomball, Texas, United States
  • 1218.75.102 Boehringer Ingelheim Investigational Site
    Tomball, Texas, United States
  • 1218.75.094 Boehringer Ingelheim Investigational Site
    Waco, Texas, United States
  • 1218.75.092 Boehringer Ingelheim Investigational Site
    Whitney, Texas, United States
  • 1218.75.019 Boehringer Ingelheim Investigational Site
    Virgnia Beach, Virginia, United States
09

References and documents

Publications

  • Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials. Clin Ther. 2014 Nov 1;36(11):1595-605. doi: 10.1016/j.clinthera.2014.07.020. Epub 2014 Sep 16. PubMed 25236917 ↗
  • Thrasher J, Daniels K, Patel S, Whetteckey J. Black/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin. Expert Opin Pharmacother. 2012 Dec;13(17):2443-52. doi: 10.1517/14656566.2012.740459. Epub 2012 Nov 8. PubMed 23134211 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2010
First posted
Sep 3, 2010
Start
Sep 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Oct 26, 2012
Last update
Jan 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01194830
Responsible party
Sponsor
First posted
Sep 3, 2010
Start date
Sep 2010
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Oct 26, 2012
Last update
Jan 29, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion